Evidence map›Paper›PMID 34307841›Full record

ArticleRNA & disease (Houston, Tex.)2017

Triggerable RNA nanodevices.

Justin Halman, Emily Satterwhite, Jaclyn Smollett, Eckart Bindewald, Lorena Parlea, Mathias Viard, Paul Zakrevsky, Wojciech K Kasprzak, Kirill A Afonin, Bruce A Shapiro

Abstract read
PubMed Full text at PMC
In one paragraph

Article in RNA & disease (Houston, Tex.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Justin HalmanDepartment of Chemistry, University of North Carolina at Charlotte, 9201 University City Boulevard, Charlotte 28223, North Carolina, USA.
Emily SatterwhiteDepartment of Chemistry, University of North Carolina at Charlotte, 9201 University City Boulevard, Charlotte 28223, North Carolina, USA.
Jaclyn SmollettDepartment of Chemistry, University of North Carolina at Charlotte, 9201 University City Boulevard, Charlotte 28223, North Carolina, USA.
Eckart BindewaldBasic Science Program, Leidos Biomedical Research, Inc., Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick 21702, Maryland, USA.
Lorena ParleaGene Regulation Chromosome Biology Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick 21702, Maryland, USA.
Mathias ViardGene Regulation Chromosome Biology Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick 21702, Maryland, USA.
Paul ZakrevskyGene Regulation Chromosome Biology Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick 21702, Maryland, USA.
Wojciech K KasprzakBasic Science Program, Leidos Biomedical Research, Inc., Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick 21702, Maryland, USA.
Kirill A AfoninDepartment of Chemistry, University of North Carolina at Charlotte, 9201 University City Boulevard, Charlotte 28223, North Carolina, USA.
Bruce A ShapiroGene Regulation Chromosome Biology Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick 21702, Maryland, USA.

Funding

Computational RNA NanodesignZIABC011061 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI SHAPIRO, BRUCE · 2009 to 2021
$12.3M
CCR NIH HHS HHSN261200800001CIntramural NIH HHS ZIA BC011061NCI NIH HHS HHSN261200800001E
6 · The paper itself

Abstract

The targeted and conditional activation of pharmaceuticals is an increasingly important feature in modern personalized medicine. Nucleic acid nanoparticles show tremendous potential in this exploit due to their programmability and biocompatibility. Among the most powerful nucleic acid specific treatments is RNA interference-based therapeutics. RNA interference is a naturally occurring phenomenon in which specific genes are effectively silenced. Recently we have developed two different strategies based on customized multivalent nucleic acid nanoparticles with the ability to conditionally activate RNA interference in diseased cells as well as elicit detectable fluorescent responses.[1,2] These novel technologies can be further utilized for the simultaneous delivery and conditional intracellular activation of multiple therapeutic and biosensing functions to combat various diseases.

Identifiers

PMID34307841
PMCPMC8301261

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.